Next Article in Journal
A Pilot Study on the Potential of RNA-Associated to Urinary Vesicles as a Suitable Non-Invasive Source for Diagnostic Purposes in Bladder Cancer
Previous Article in Journal
Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
Previous Article in Special Issue
HEXIM1, a New Player in the p53 Pathway
Cancers 2014, 6(1), 166-178; doi:10.3390/cancers6010166
Article

Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex

1,* , 1
,
2
,
3
,
3
 and
1
Received: 22 November 2013 / Revised: 10 January 2014 / Accepted: 13 January 2014 / Published: 21 January 2014
(This article belongs to the Special Issue The p53 Pathway in Cancers)
View Full-Text   |   Download PDF [1110 KB, 22 January 2014; original version 21 January 2014]   |   Browse Figures

Abstract

Focal Adhesion Kinase (FAK) is a non-receptor kinase that plays an important role in many cellular processes: adhesion, proliferation, invasion, angiogenesis, metastasis and survival. Recently, we have shown that Roslin 2 or R2 (1-benzyl-15,3,5,7-tetraazatricyclo[3.3.1.1~3,7~]decane) compound disrupts FAK and p53 proteins, activates p53 transcriptional activity, and blocks tumor growth. In this report we performed a microarray gene expression analysis of R2-treated HCT116 p53+/+ and p53−/− cells and detected 1484 genes that were significantly up- or down-regulated (p < 0.05) in HCT116 p53+/+ cells but not in p53−/− cells. Among up-regulated genes in HCT p53+/+ cells we detected critical p53 targets: Mdm-2, Noxa-1, and RIP1. Among down-regulated genes, Met, PLK2, KIF14, BIRC2 and other genes were identified. In addition, a combination of R2 compound with M13 compound that disrupts FAK and Mmd-2 complex or R2 and Nutlin-1 that disrupts Mdm-2 and p53 decreased clonogenicity of HCT116 p53+/+ colon cancer cells more significantly than each agent alone in a p53-dependent manner. Thus, the report detects gene expression profile in response to R2 treatment and demonstrates that the combination of drugs targeting FAK, Mdm-2, and p53 can be a novel therapy approach.
Keywords: Focal Adhesion Kinase; p53; Mdm-2; Nutlin; gene expression profiling; microarrays; combination therapy Focal Adhesion Kinase; p53; Mdm-2; Nutlin; gene expression profiling; microarrays; combination therapy
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Golubovskaya, V.M.; Ho, B.; Conroy, J.; Liu, S.; Wang, D.; Cance, W.G. Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex. Cancers 2014, 6, 166-178.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert